Latest Financial Results
Q2 2018
Quarter Ended Jun 30, 2018
Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Stock Information
Symbol
Nasdaq: SCYXPrice
Change
Daily Volume
52-week Low/High
Day Low/High
Investor Contact Information
Investor Relations
Argot Partners
Natalie Wildenradt
T: 212-600-1902
natalie@argotpartners.com
Media Relations
MacDougall Biomedical Communications
George E. MacDougall
T: 781-235-3093
george@macbiocom.com
Transfer Agent
American Stock Transfer & Trust Company, LLC
10150 Mallard Creek Road
Suite 307
Charlotte, NC 28262
T: 800-937-5449